

30 January 2024

The Manager
ASX Market Announcements
Australian Securities Exchange
Exchange Centre
Level 4
20 Bridge Street
Sydney NSW 2000

Amcil Limited
ABN 57 073 990 735
Level 21, 101 Collins St
Melbourne VIC 3000
T 03 9650 9911
F 03 9650 9100
invest@amcil.com.au
amcil.com.au

Electronic Lodgement

AMCIL Limited Half Yearly Results Webcast Presentation

Please find attached the presentation to be given at the Company's half yearly financial results update being held today **Tuesday 30 January 2024 at 3.30pm** (AEST).

Webcast

To join the webcast please use the following link: <u>Webcast Link</u> (This link will open directly in your internet browser).

The shareholder presentation material will be made available through our website www.amcil.com.au.

Yours faithfully

Matthew Rowe Company Secretary ASX Release authorised by the Company Secretary

Half Year Results

January 2024





Disclaimer

AMCIL Limited and Australian Investment Company Services Limited (AFSL: 303209) and each of their respective directors, officers and agents (together the *Disclosers*) have prepared the information contained in these materials in good faith. However, no warranty (express or implied) is made as to the accuracy, completeness or reliability of any statements, estimates or opinions or other information contained in these materials (any of which may change without notice) and to the maximum extent permitted by law, the Disclosers disclaim all liability and responsibility (including, without limitation, any liability arising from fault or negligence on the part of any or all of the Disclosers) for any direct or indirect loss or damage which may be suffered by any recipient through relying on anything contained in or omitted from these materials. Any reader is strongly advised to make their own enquiries and seek independent professional advice regarding information contained in these materials.

These materials have been prepared solely for the purpose of information and do not constitute, nor are they intended to constitute advice nor an offer or invitation to any person to subscribe for, buy or sell any shares or any other securities.



Interim Result Summary – Six months to 31 December 2023




	2023			2023	
Profit for the Half-Year	\$4.1m	\$4.1 million in 2022	Total Shareholder Return	8.5%	Share price plus dividend including franking*
Fully Franked Interim Dividend	1. 0¢	1.0 cent in 2022	Management Expense Ratio	0.46%	0.66% in 2022
Total Portfolio Return	11.7% Including franking*	S&P/ASX 200 Accumulation Index including franking* 8.3%	Total Portfolio	\$369.9m	Including cash at 31 December. \$323.6 million in 2022

^{*} Assumes an investor can take full advantage of the franking credits.

Share Price Relative to Net Tangible Asset (NTA)






31 December 2023

NTA: \$1.18


Share price: \$1.03



Portfolio Performance – Returns to 31 December 2023

including franking





AMCIL's Investment Objectives

- ✓ Attractive returns through strong capital growth in the portfolio over the medium to long term
- ✓ The generation of fully franked dividends.

Assumes an investor can take full advantage of the franking credits.

AMCIL on occasions incurs realised capital gains tax on the sale of shares. Not all the of the franking generated from realised capital gains is paid out as dividends and is therefore not included in these performance figures.

Past performance is not indicative of future performance.

dividends, including franking

The Key Unique Benefits of an Investment in AMCIL



The key unique benefits of AMCIL are the combination of:



Focused portfolio invested in quality companies where holding size is not determined by the index weighting



Alignment of interests

- ✓ Comparatively low management cost
- √ No performance fees
- ✓ Equity ownership by directors and staff



Tax effectiveness from a low turnover, long term investment approach

A Closer Look at AMCIL's Investment Approach



Attributes of a high-quality company that we seek:

- Unique assets that are hard to replicate or have an Industry leadership position (or developing one)
- Sustainability of competitive advantage
- Not unduly burdened by external risk factors
- Conservative balance sheets (low debt)
- Consistency of earnings
- Run by effective, passionate management with ownership alignment
- Positive business/operating trends

Why this matters:


- The presence of these factors drives a competitive advantage
- Which leads to high return on capital
- And allows for reinvestment opportunities to drive growth
- Which allows for market share capture and further enhancement of leadership position
- Which combines to deliver long term shareholder value creation

We seek to buy these companies when we identify long term value And reduce or exit when they no longer meet these characteristics

AMCIL's Portfolio Diversification



A spread of high quality of **small and large businesses** operating across **different sectors** and **geographies** gives us long term confidence across a variety of possible equity market and economic conditions.





Recent Portfolio Activity



Exited	Reduced
medibank	JamesHardie de la companya de la com
(Purchased and Exited)	တ်
FINEOS	Woolworths
_	All Auckland Airport
	Define to the second se
	W estpac
	_=Transurban

Added	New
🜞 nab	Altıum
‰ idp	MINERAL RESOURCES
Gentrack	ipd (
ASX	<u>Objective</u>
w oodside	
• macquarie TECHNOLOGY GROUP	

Our Investment Philosophy in Practice – New Holdings



Initiated positions in companies with attractive characteristics:





- Provider of leading circuit board design software
- ✓ Aligned management
- ✓ Long growth runway
- ✓ High return on capital
- ✓ No debt, high Return on Equity
- ✓ Strong R&D/reinvestment





- Leading diversified mining company
- ✓ Quality assets
- ✓ Owner driver business
- Attractive production growth outlook
- ✓ Strong R&D/reinvestment

Objective




- Leading provider of software to government and regulated industries
- Owner driver business
- ✓ Long growth runway
- ✓ Recurring revenue profile
- ✓ No debt
- ✓ Strong R&D/reinvestment

Our Investment Philosophy in Practice – Recent Transactions




Continue to seek value in quality, out of favour companies:



Our Investment Philosophy in Practice – Recent Transactions



Continue to seek value in quality, out of favour companies:



Our Investment Philosophy in Practice



Established or added to holdings in growing, developing companies with owner driver characteristics:











Maintained conviction where fundamentals are sound:

- Observed significant dislocation in quality healthcare names due to concerns surrounding the impact of weight-loss drugs.
- AMCIL has maintained substantial positions in CSL and ResMed through the volatility.

Trimmed holdings where valuation became less appealing:









Portfolio Well Positioned For The Future



Woodside

Commonwealth

Eneray

Bank

inab


Mestpac

'Asset Play' Companies

Santos

AMCIL's portfolio is well placed to navigate a wide range of economic outcomes:

Growth Companies 📀 macquarie ARB **CAR Group** netwealth **Equity Trustees** reece James Hardie Cochlear Breville REA Group **Altium** Goodmar III I wisetech **TEMPLE** Beamtree **%**idp WEBSTER 'ıl' alobal MINERAL RESOURCES gentrack[™] Fisher & Paykel xero **Objective** 1.1/1/1/12/11/96



ResMed



Outlook



Key questions on our minds:

- Inflation is declining, is this sustainable and what are the implications for interest rates?
- Stock valuations have rebounded as interest rate expectations have eased – is this sustainable?
- ➤ Is the environment becoming more challenging for companies to generate earnings growth?

While AMCIL is not immune to external risks, our approach positions the portfolio to weather market volatility:

Continued focus on quality companies

Seeking to add to these companies when we see value

Backing aligned management teams

Share prices are driven by earnings growth in the long term

Strong balance sheets creates resilience and protects against rising interest costs

A/MCIL